Showing 1311-1320 of 1655 results for "".
- Optometry and Vision Science Names New Editor-in-Chiefhttps://modernod.com/news/optometry-and-vision-science-announces-new-editor-in-chief/2481744/The American Academy of Optometry (AAO) announced that David Elliott, PhD, FCOptom, FAAO, is the new editor-in-chief of Optometry and Vision Science (OVS). Mr. Elliott succeeds Michael Twa, OD, PhD, FAAO, who is stepping down from the role after 7 years.
- BostonSight Scleral to Host Webinar on Using Fitkit Trial Lens Set for Successful Fittinghttps://modernod.com/news/bostonsight-scleral-to-host-webinar-on-using-fitkit-trial-lens-set-for-successful-fitting/2480885/BostonSight Scleral will host a one-hour scleral lens webinar on Tuesday, June 14, at 8 pm EDT with Suzanne Walter Sherman, OD, FAAO, and Steven Sorkin, OD, on how to get the most out of a BostonSight Scleral FitKit.
- American Academy of Optometry Foundation Announces Award Recipientshttps://modernod.com/news/american-academy-of-optometry-foundation-announces-award-recipients/2479474/Jonathan D. Lam, MD, OD, was this year’s recipient of the Hopkins Comprehensive Eye Care Award. Dr. Lam is a primary care/ocular disease resident at the Chinle Comprehensive Health Care Facility in Chinle, Arizona. Douglas W. Hopkins, OD, FAAO, was a leader within the Primary Care Section
- Oculus Names New Medical Directorhttps://modernod.com/news/oculus-names-new-medical-director/2478589/Oculus has announced that William Tullo, OD, FAAO, joined the company as a Medical Director on November 2nd, 2020. In this newly developed role, Dr. Tullo will provide clinical guidance and educate medical eye profess
- FDA Notifies Ocular Therapeutix that SOL-R Trial is Appropriate as a Registrational Study in Wet AMDhttps://modernod.com/news/fda-notifies-ocular-therapeutix-that-sol-r-trial-is-appropriate-as-a-registrational-study-in-wet-amd/2482388/Ocular Therapeutix announced that it has received a written response from the FDA that the phase 3 SOL-R clinical trial is appropriate for use as the company’s second adequate and well controlled study of Axpaxli (axitinib intravitreal implant, also known as OTX-TKI) for the
- Enrollment Begins for Ocular Therapeutix’s Axpaxli Phase 3 SOL-R Wet AMD Studyhttps://modernod.com/news/ocular-therapeutixs-axpaxli-phase-3-sol-r-wet-amd-study-begins-enrollment/2482382/Ocular Therapeutix announced that the first patients have been enrolled in the phase 3 SOL-R clinical trial evaluating repeat dosing of Axpaxli (axitinib intravitreal implant, also known as OTX-TKI) for the treatment of patients with wet age-related macular degeneration (wet AMD). Accor
- Dr. Louis R. Pasquale Winner of the Glaucoma Foundation's 2023 Robert Ritch Awardhttps://modernod.com/news/dr-louis-r-pasquale-winner-of-the-glaucoma-foundations-2023-robert-ritch-award/2481629/Louis R. Pasquale, MD, FARVO, has been named the 2023 recipient of The Glaucoma Foundation’s (TGF) Robert Ritch Award for Innovation and Excellence in Glaucoma. Created in 2008, the award recognizes the contributions of individuals who have played a significant and unique role in promoting
- Alcon Names Daniel M. Miller, MD, PhD, Senior Scientific Advisor to Alcon's R&D team PDFhttps://modernod.com/news/alcon-names-daniel-m-miller-md-phd-senior-scientific-advisor-to-alcons-rd-team-pdf/2481584/Alcon announced that the highly esteemed ophthalmologist, Daniel M. Miller, MD, PhD, will join Alcon as a member of the Research and Development (R&D) team. Dr. Miller is a fellowship-trained medical and surgical retina specialist. He will serve as a Senior Scientific Advisor to Alc
- iOR Partners Appoints Health Care Industry Veteran James R. Williams as New President and CEOhttps://modernod.com/news/ior-partners-welcomes-health-care-industry-veteran-as-new-president-and-ceo/2481068/iOR Partners announced that James R. Williams has been appointed to serve as the company’s new President and CEO. Mr. Williams joined iOR as Chief Operating Officer (COO) earlier this year and served on the iOR Board of Directors for 2 years. Mr. Williams brings over 30
- David R. Guyer, MD, to Step Down from Iveric Bio Board to Rejoin Venture Fundhttps://modernod.com/news/david-r-guyer-md-to-step-down-from-iveric-bio-board-to-rejoin-venture-fund/2479050/Iveric bio announced that David R. Guyer, MD, co-founder and Executive Chairman, is stepping down from the Iveric Bio Board after 14 years, effective following Iveric Bio’s 2021 Annual Stockholder Meeting scheduled to be held on May 19, 2021. Dr. Guyer has served as the Chairman of Iveric’